From the recently concluded Roth conference investor presentation,
• Phase 1b completion and results due imminently (ahead of recent expectations)
• Lessons from other trials currently running? • In current Phase 1b breast & ovarian cancer trials for PTX-200, interim analysis showed encouraging efficacy
PTX-200 has lots of supportive data and efficacy signals that combine to give confidence leading into the Phase 1b/2 trial.
Sounds like a positive announcement has been signalled...would be very strange if the if all the results were negative.
PTX Price at posting:
9.8¢ Sentiment: Buy Disclosure: Held
